Company profile: MiNK Therapeutics
1.1 - Company Overview
Company description
- Provider of allogeneic invariant natural killer T (iNKT) cell therapies and immune technologies, including AGENT-797 for solid tumors and severe ARDS; native iNKT therapies; engineered iNKT therapies with CARs and bispecific engagers; and platforms (CARDIS and IgG-based bispecific iNKT cell engagers) for discovering, optimizing, and developing targeted cancer treatments.
Products and services
- AGENT-797: An allogeneic invariant natural killer T-cell therapy evaluated in clinical trials for treating solid tumors and severe ARDS
- Engineered iNKT Cell Therapies: Genetically modified iNKT cells, including CARs and bispecific cell-engagers, for enhanced targeting and treatment of cancers
- Native iNKT Cell Therapies: Invariant natural killer T cells used without genetic modification to treat solid tumor cancers and other immune diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to MiNK Therapeutics
ImaginAb
HQ: United States
Website
- Description: Provider of molecular imaging solutions for cancer and autoimmune disease management by re-engineering antibodies into small proteins. Offers non-invasive CD8 ImmunoPET to visualize CD8-positive T cells across the body and assess treatment effectiveness, develops therapeutic radiopharmaceuticals using antibody fragment platforms, and supports clinical trials through CD8 ImmunoPET implementation and partnerships.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImaginAb company profile →
Verastem
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies targeting RAS/MAPK pathway–driven cancers, developing avutometinib, a RAF/MEK clamp designed to block RAF and MEK signaling in the RAS pathway, and defactinib, a FAK inhibitor used with avutometinib to block compensatory FAK activation and enhance tumor growth blockade.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verastem company profile →
Quanticel
HQ: United States
Website
- Description: Provider of oncology drug discovery, leveraging a proprietary single-cell genomic analysis platform for human cancer to enable the discovery and development of breakthrough, first-in-class cancer therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quanticel company profile →
Theranostics Health
HQ: United States
Website
- Description: Provider of proteomics-based diagnostics and research services for drug development companies, developing diagnostic tests to enable personalized cancer therapies tailored to each patient’s tumor, utilizing Laser Capture Microdissection (LCM) and Reverse-phase Protein MicroArrays (RPMA) assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theranostics Health company profile →
Point Biopharma
HQ: United States
Website
- Description: Provider of radioligand therapies for cancer, with a globally focused platform for the clinical development and commercialization of radioligands. Combines a portfolio of radiopharmaceutical assets with a seasoned management team and expertise in radioisotopes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Point Biopharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for MiNK Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to MiNK Therapeutics
2.2 - Growth funds investing in similar companies to MiNK Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for MiNK Therapeutics
4.2 - Public trading comparable groups for MiNK Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →